1. Scrip
  2. >>Therapy Areas

Pfizer's Xeljanz Post-Marketing Study Raises Safety Alarms

 
• By Jessica Merrill

A safety study of Pfizer's anchor immunology brand Xeljanz showed higher rates of heart attacks and cancer versus a TNF inhibitor.

flashing light
Pfizer's Xeljanz shows safety issues in a new study • Source: Shutterstock

Pfizer Inc.'s oral JAK inhibitor Xeljanz (tofacitinib) is an anchor franchise the company hopes to use to build out a broader immunology portfolio, but renewed safety concerns could thwart the brand's future growth prospects. Increased risks of cardiovascular disease and cancers associated with the drug could also cast a cloud over newer JAK inhibitors like AbbVie Inc.'s Rinvoq (upadactanib) and Eli Lilly and Company's Olumiant (baricitinib).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.